Oxandrolone vs Oxymetholone

Oxandrolone (S-tier) vs Oxymetholone (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

Oxandrolone — tier S

an oral 17-alpha-alkylated androgen with measured human pharmacokinetics and controlled burn data, whose US approvals were withdrawn in 2023 after FDA safety and effectiveness review.

the burn outcome and human half-life are real, and so are the withdrawal, boxed liver warning, lipid injury, and endocrine risks.

31.6 vs 43.3 days hospital stay in one severe-burn RCT · half-life 10.4 hours in younger volunteers and 13.3 hours in older adults in the historical Oxandrin label · androgens

Oxymetholone — tier S

an oral 17-alpha-alkylated anemia drug with legal FDA approval but no active US marketing, controlled human lean-mass data, severe dose-related hepatic toxicity, and animal-only terminal half-life.

oxymetholone has clear human anabolic and wasting outcomes, and those same trials document a severe hepatic and lipid cost that cannot be separated from the evidence grade.

+4.2 kg lean body mass at 100 mg/day in one 12-week RCT · half-life no validated human terminal half-life; 5.56 hours in male F344/N rats after 30 mg/kg oral gavage · androgens

at a glance

• Oxandrolone: tier S · 31.6 vs 43.3 days hospital stay in one severe-burn RCT
• Oxymetholone: tier S · +4.2 kg lean body mass at 100 mg/day in one 12-week RCT

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.